Yi-Nao-Jie-Yu Prescription Relieves Post-Stroke Depression by Mitigating Ferroptosis in Hippocampal Neurons Via Activating the Nrf2/GPX4/SLC7A11 Pathway

Yuan Zhang, Qisheng Tang, Jin Yao, Hongwei Liu, Chen Xu, Zi‐Kuan Guo, Shuqing Liu, Ruizhen ZhaoJournal of Neuroimmune Pharmacology 2025 · DOI

Abstract

Post-stroke depression (PSD) significantly impacts patient recovery and quality of life. This study investigates the therapeutic effects of the Yi-nao-jie-yu (YNJY) prescription, a traditional Chinese medicine formula, on PSD. Using a rat model, we demonstrate that YNJY alleviates depressive-like behaviors and hippocampal neuronal damage. The mechanism involves the activation of the Nrf2/GPX4/SLC7A11 signaling pathway, which inhibits ferroptosis—a form of iron-dependent cell death. These findings suggest YNJY is a promising clinical agent for PSD treatment.

Introduction

Post-stroke depression (PSD) is a frequent and debilitating complication of stroke, characterized by anxiety, hopelessness, and a lack of interest in life. While standard antidepressants are available, they often suffer from poor tolerability and significant side effects. Recent research has identified ferroptosis—a programmed cell death pathway driven by iron accumulation and lipid peroxidation—as a key driver of hippocampal damage in depression. This study explores whether the YNJY prescription, known for its neuroprotective properties, can alleviate PSD by targeting this biological "kill switch."

Methods

The researchers employed a multi-level experimental approach combining in vivo animal models and in vitro cellular assays.

Animal Model and Treatment

A PSD rat model was established using sixty male Sprague Dawley (SD) rats. The protocol involved inducing an intracerebral hemorrhage (ICH) followed by four weeks of Chronic Unpredictable Mild Stress (CUMS).

Experimental timeline for the PSD rat model, illustrating the stages of adaptive feeding, ICH induction, and recovery.

Rats were treated with low or high doses of YNJY. To confirm the mechanism, the Nrf2 inhibitor ML385 was administered to specific groups. Behavioral testing included the Sucrose Preference Test, Tail Suspension Test (TST), Forced Swimming Test (FST), and Open-Field Test (OFT).

Molecular and Cellular Analysis

Transmission Electron Microscopy (TEM) was used to assess mitochondrial damage. Western blotting and qRT-PCR measured protein and gene expression, while specialized kits tracked iron levels, Reactive Oxygen Species (ROS), and Malondialdehyde (MDA). Primary rat hippocampal neurons were also used in vitro to confirm the pathway's necessity.

Results

Behavioral Recovery

YNJY treatment significantly reversed depressive-like behaviors. High-dose YNJY (YNJY-H) increased sucrose preference and decreased immobility time in the TST and FST. In the Open-Field Test, YNJY-treated rats showed a marked increase in rearing and crossing counts compared to the untreated PSD group.

Behavioral assessment results (F: Rearing counts, G: Crossing counts) showing significant improvement in YNJY-treated groups compared to the PSD model.

Inhibition of Ferroptosis

Biochemical analysis revealed that YNJY treatment led to a dramatic decrease in iron (Fe), ROS, and MDA levels in the hippocampus, while boosting protective antioxidants like SOD and GSH. TEM imaging confirmed that YNJY prevented mitochondrial shriveling, a hallmark of ferroptosis.

Pathway Activation

Western blots confirmed that YNJY upregulated the expression of Nrf2, GPX4, and SLC7A11 proteins. The "rescue" experiment using the Nrf2 inhibitor ML385 showed that blocking Nrf2 abolished the protective effects of YNJY, proving that the Nrf2/GPX4/SLC7A11 pathway is the primary mechanism of action.

Discussion and Conclusion

This study confirms that ferroptosis is a major driver of hippocampal damage in PSD and that the YNJY prescription effectively mitigates this damage. YNJY is a "poly-pharmacological" intervention consisting of five herbs: Acanthopanax senticosus, Curcuma longa, Fructus Gardeniae sp., Schisandra chinensis, and Bupleurum. This complex mixture provides a robust therapeutic effect by activating the body's master antioxidant regulator, Nrf2.

While these results are promising, future work is needed to identify the specific active compounds within the formula and to conduct clinical trials to confirm safety and efficacy in human patients. Nonetheless, YNJY represents a significant step forward in bridging traditional wisdom with modern molecular biology for the treatment of post-stroke depression.

Summary updated

Abstract

Post-stroke depression (PSD) poses a serious impact on patients' life quality. Effective drugs to treat this annoying disease are still being sought. Yi-nao-jie-yu (YNJY) prescription has been found to relieve PSD; however, the underlying mechanisms remain unelucidated. This work elucidated the therapeutic effects and mechanisms underlying YNJY prescription in PSD. PSD rat model was treated with YNJY prescription and ML385. Depression-like behaviors of rats was appraised. Hematoxylin-eosin, Nissl, and NeuN immunofluorescence staining were performed to observe hippocampal neuronal damage. Transmission electron microscopy was used to assess hippocampal mitochondrial damage. Commercial kits and western blotting were adopted to research ferroptosis-related factors and Nrf2/GPX4/SLC7A11 signals. In vitro experiments were performed using rat hippocampal neurons to explore the mechanism by which YNJY prescription relieves PSD. In PSD rats, YNJY prescription relieved depression-like behaviors, attenuated hippocampal neuronal damage, mitigated hippocampal ferroptosis and mitochondrial damage, and activated hippocampal Nrf2/GPX4/SLC7A11 pathway. By in vitro experiments, erastin treatment exacerbated hippocampal neuronal damage, ferroptosis, mitochondrial damage, and lipid peroxidation; however, YNJY prescription abolished these erastin-induced effects. In the erastin-treated hippocampal neuronal model of PSD, ML385 treatment increased ferroptosis, hippocampal neuronal damage, and lipid peroxidation; however, YNJY prescription counteracted these ML385-induced effects. By in vivo study, ML385 reversed the relief of YNJY prescription on depressive-like behaviors of PSD rats, and the inhibition on ferroptosis in PSD rats' hippocampus. YNJY prescription relieves PSD by blocking ferroptosis via activating the Nrf2/GPX4/SLC7A11 pathway. It may be a promising agent for treating PSD clinically.
BibTeX
@article{zhang2025yi,
  author = {Yuan Zhang and Qisheng Tang and Jin Yao and Hongwei Liu and Chen Xu and Zi‐Kuan Guo and Shuqing Liu and Ruizhen Zhao},
  title = {{Yi-Nao-Jie-Yu Prescription Relieves Post-Stroke Depression by Mitigating Ferroptosis in Hippocampal Neurons Via Activating the Nrf2/GPX4/SLC7A11 Pathway}},
  journal = {Journal of Neuroimmune Pharmacology},
  year = {2025},
  doi = {10.1007/s11481-024-10167-1},
}
Figure